Coagulation Analyzers - Market Insights, Competitive Landscape, and Market Forecast - 2030

Coagulation Analyzers Market By Product Type (Instruments [Automated Analyzers, Semi-Automated Analyzers, And Manual Analyzers] And Reagents And Consumables), Test Type (Fibrinogen Testing, Activated Clotting Time Testing, D-Dimer Testing, Prothrombin Time, And Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, And Others), End-User (Hospitals, Diagnostic Centers, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of cardiovascular diseases and bleeding disorders and the surging technological advancements in product portfolio coupled with increasing product development activities

The global coagulation analyzers market was valued at USD 3,344.16 million in 2022 and is likely to register a CAGR of 5.37% during the forecast period from 2024 to 2030 to reach USD 4,564.45 million by 2030. The demand for coagulation analyzers is being boosted by a rise in the increasing prevalence of various cardiovascular diseases and bleeding disorders including coronary heart disease, peripheral arterial disease, hemophilia, von Willebrand disease, and others, surge in awareness programs and initiatives, increasing product development activities such as product launches and regulatory approvals, among others are thereby contributing to the overall growth of the coagulation analyzers market during the forecast period from 2024-2030.

Coagulation Analyzers Market Dynamics:

The coagulation analyzers market is witnessing growth owing to various factors, one of the key factors being the growing prevalence of cardiovascular diseases.

According to American Heart Association 2022 data, globally about 244.1 million people were living with coronary (ischemic) heart disease in 2020. The data provided by British Heart Foundation 2022 mentioned that, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men.

The increasing number of cardiovascular surgeries where coagulation analyzers are employed to assess possible risk for hypercoagulability or thrombophilia before, during, and after the procedure is also going to accelerate the demand for coagulation analyzers. For instance, as per the Organisation for Economic Co-operation and Development (OECD) 2023, nearly 9,451 coronary artery bypass graft procedures were performed in the United Kingdom in 2020.

Also, approximately 38,859 coronary artery bypass graft procedures were performed in Germany in the same year. The same source stated that 26,355 transluminal coronary angioplasty procedures were performed in Switzerland, in 2020. In the same year, 53,993 transluminal coronary angioplasty procedures were performed in Spain.

Coagulation analyzers can monitor the effectiveness of heparin therapy, an anticoagulation therapy used during cardiopulmonary bypass (CPB) surgery, angioplasty, and other cardiovascular procedures.

The increasing number of individuals with bleeding disorders such as hemophilia, von Willebrand disease, and others is another major factor driving the growth of the coagulation analyzers market.

The results from the World Federation of Hemophilia (WFH) Annual Survey 2021 say that, from 1999 to 2020, around 429,232 people were identified and reported with bleeding disorders. This includes 256,840 cases of hemophilia, 98,293 of von Willebrand disease (VWD), and 74,099 cases of other bleeding disorders.

Chronic blood disorders have a significant impact on the health and quality of life of patients and their families. They can cause pain, loss of normal functioning, depression, anxiety, financial burden, long-term hospitalization, and even death. Devices such as coagulant analyzers help in detecting clot deficiencies, measuring coagulation pathways speed, and thrombolin levels and are also used to monitor the effects of drugs on whole blood. Therefore, early detection of heart conditions and other bleeding disorders using coagulation analyzers is very much important, and will thereby promote the growth of the global coagulation analyzers market during the forecast period.

Therefore, the above-mentioned factors are contributing to the growth of the coagulation analyzers market during the forecast period from 2024-2030.

However, a lack of skilled professionals leading to errors, an increasing number of product recalls, and others may restrict the coagulation analyzer's market growth.

Coagulation Analyzers Market Segment Analysis:

Coagulation Analyzers market by Product Type (Instruments [Automated Analyzers, Semi-Automated Analyzers, and Manual Analyzers] and Reagents and Consumables), Test Type (Fibrinogen Testing, Activated Clotting Time Testing, D-Dimer Testing, Prothrombin Time, and Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the coagulation analyzers market, the reagents and consumables category held the highest revenue of USD 2,364.06 million in 2022. This can be ascribed to the applications and advantages related to the segment.

In a coagulation analyzer, a reagent is used to detect and measure different components in a blood platelet sample. The availability of different types of reagents with variable characteristics and applications is responsible for their increased demand in the market. These reagents can be produced synthetically either from a human or an animal source.

They can be present in different forms: lyophilized, liquid, and powder. For instance, TriniCLOT PT Reagents are lyophilized thromboplastins from either rabbit or human sources.

Further, Phospholin ES APTT reagent is an ellagic acid-based reagent, a naturally occurring reagent with soybean phospholipids, buffers, stabilizers, and preservatives. Phospholin ES is intended for use as an activated partial thromboplastin time (APTT) reagent. The STA®-Liquid Fib is a new liquid reagent for the quantitative determination of fibrinogen levels which provides results in less than 5 minutes.

The consumables consist of test strips, capillary tubes, cuvettes, and others. The consumables are available in different variations, making them easy for end-user. For instance, Mission® PT/INR Test Strips, are individually wrapped strips that maintain the stability of a device. It is available in 12 and 48 packs.

Hence, owing to all the aforementioned factors, the market will experience an increased demand for reagents and consumables thus driving the coagulation analyzers market during the forecast period.

North America is expected to dominate the overall Coagulation Analyzers Market:

Among all the regions, North America is estimated to account for the largest share of 38.69% in the coagulation analyzers market in the year 2023. Owing to the factors such as the increasing prevalence of blood disorders such as hemophilia, von Willebrand disease, sickle cell disease, and others will influence the growth of the coagulation analyzers in the region. Furthermore, increasing healthcare expenditure, and rising research and development activities in the region associated with the surging launch and approval of new coagulation analyzers are also driving the market growth of coagulation analyzers in North America.

According to National Center on Birth Defects and Developmental Disabilities under the Centers for Disease Control and Prevention (CDC) 2022, sickle cell anemia affects about 100,000 Americans. As per the same source, Hemophilia A affects 1 in 5,000 male births and each year about 400 babies are born with hemophilia A in the United States.

According to statistics by the Canadian Hemophilia Society (2023), Hemophilia A affects about 2,500 Canadians and Hemophilia B affects approximately about 600 Canadians every year on average. But recent data published by Hemophilia Ontario suggests that the estimated number of hemophilia cases in Canada was more than the estimated numbers, affecting approximately 4,000 Canadians annually.

Further, according to statistics by the CDC (2023), the estimated number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) is 900,000 people on average each year in the United States. Coagulation analyzers are also employed in testing for the effect of blood thinners and anticoagulants in such patients as well.

Coupled with the factors mentioned above, strategic activities such as product launches and approvals, mergers, acquisitions, partnerships, investments, and others also help in boosting regional product demand. For instance, in December 2022, Durham-based medical device developer Hemosonics received the US FDA approval for its Quantra Hemostasis System with QStat Cartridge to assist doctors in evaluating whole blood samples to determine how well the blood is clotting. Thus, such strategic steps help to increase the demand for coagulation analyzers, thereby driving the North America coagulation analyzers market forward during the forecast period.

Coagulation Analyzers Market Key Players:

Some of the key market players operating in the coagulation analyzers market include Abbott, Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Maccura Biotechnology Co., Ltd., Bio-Group Medical System srl, Genrui Biotech Co., Ltd., Tokuyama Corporation, Stago, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BIOLABO S.A.S., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International S.p.A, Erba Mannheim, ACON Laboratories, Inc., Haemonetics Corporation, and others.

Recent Developmental Activities in the Coagulation Analyzers Market:

In March 2023, Sysmex and Siemens Healthineers Establish a Global Agreement to Supply Hemostasis Instruments and Reagents as OEMs, under which each company will supply the other with their products in the diagnostic field of hemostasis on an OEM basis.

In February 2022, Horiba UK, a subsidiary of Horiba Medical, launched the new high throughput hemostasis analyzer known as the new Yumizen G1550 automated hemostasis analyzer and Microsemi CRP LC-767G POC hematology analyzer in the UK.

In October 2021, Trivitron Healthcare, a leading medical devices company announced the launch of a new line of Coagulation Analyzer products manufactured by Diagon Ltd

In July 2021, Sysmex Europe launched two new automated blood coagulation analyzers, CN-3500 and CN-6500, in specific countries in the EMEA region. They are targeted at medium- and large-scale hospitals and commercial labs, as well as other facilities.

Key Takeaways from the Coagulation Analyzers Market Report Study

Market size analysis for current coagulation analyzers market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global coagulation analyzers market.

Various opportunities available for the other competitor in the coagulation analyzers market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current coagulation analyzers market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for coagulation analyzers market growth in the coming future?

Target Audience who can be benefited from this Coagulation Analyzers Market Report Study

Coagulation analyzers products providers

Research organizations and consulting companies

Coagulation analyzers-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in coagulation analyzers

Various End-users who want to know more about the coagulation analyzers market and the latest technological developments in the coagulation analyzers market.

Frequently Asked Questions for the Coagulation Analyzers Market:

1. What are coagulation analyzers?

Coagulation analyzers or hemostasis analyzers are widely used point-of-care (POC) testing devices for measuring blood clotting characteristics. A coagulation analyzer can be used to test the coagulation efficiency of blood as well as thrombolin and thromboplastin levels in as low as a few minutes. It provides the measurement of blood platelet levels in a fast and simple process and is used for the diagnosis of bleeding disorders such as hemophilia.

2. What is the market for global coagulation analyzers?

The global coagulation analyzers market was valued at USD 3,344.16 million in 2022 and is likely to register a CAGR of 5.37% during the forecast period from 2024 to 2030 to reach USD 4,564.45 million by 2030.

3. What are the drivers for the global coagulation analyzers market?

The demand for coagulation analyzers is primarily being heightened by the increasing prevalence of blood disorders and their risk factors, increasing prevalence of cardiovascular diseases, increasing product development activities, funding, awareness programs, launches for coagulation analyzers by key players, technological advancements in the product portfolio, among others, thereby contribute to the overall growth of the coagulation analyzers market during the forecast period from 2024-2030.

4. Who are the key players operating in the global coagulation analyzers market?

Some of the key market players operating in the coagulation analyzers market include Abbott, Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Maccura Biotechnology Co., Ltd., Bio-Group Medical System srl, Genrui Biotech Co., Ltd., Tokuyama Corporation, Stago, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BIOLABO S.A.S., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International S.p.A, Erba Mannheim, ACON Laboratories, Inc., Haemonetics Corporation, and others.

5. Which region has the highest share in the coagulation analyzers market?

North America is expected to dominate the overall coagulation analyzers market during the forecast period from 2024-2030. Factors such as the increasing prevalence of blood disorders such as hemophilia, von Willebrand disease, sickle cell disease, and others will influence the growth of coagulation analyzers in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, regulatory approval for new devices, and others also helped the market growth in this region.